Literature DB >> 8077701

Decreased collagenase expression in cultured systemic sclerosis fibroblasts.

K Takeda1, A Hatamochi, H Ueki, M Nakata, Y Oishi.   

Abstract

One cause of the excessive deposition of collagen in systemic sclerosis is thought to be abnormal functioning of fibroblasts. The purpose of this study is to determine whether there is decreased expression of collagenase in systemic sclerosis fibroblasts. In this study, we analyzed collagen and collagenase expression in dermal fibroblasts derived from eight patients with systemic sclerosis and compared the findings with those from nine sex- and age-matched healthy subjects. Increased collagen synthesis accompanying enhanced mRNA levels was observed in two of eight strains, whereas all eight strains showed remarkable decreases in collagenase activity and production. There were no differences in the levels of collagenase mRNA between the systemic sclerosis strains and the normal strains. Results suggest that decreased collagenase expression is a characteristic of systemic sclerosis fibroblasts, and both increased collagen expression and decreased collagenase expression in systemic sclerosis fibroblasts may result in the excessive accumulation of collagen in patients with systemic sclerosis. It is also suggested that decreased collagenase expression is altered at translational and/or post-translational levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077701     DOI: 10.1111/1523-1747.ep12394936

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  18 in total

1.  Collagen turnover is diminished by different clones of skin fibroblasts from early- but not late-stage systemic sclerosis.

Authors:  Camilo S Zurita-Salinas; Edgar Krötzsch; Lino Díaz de León; Jorge Alcocer-Varela
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

2.  Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

4.  Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis.

Authors:  G Birkenmeier; R Frank
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

Review 5.  Functional autoantibodies in systemic sclerosis pathogenesis.

Authors:  Angela Kill; Gabriela Riemekasten
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

6.  Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.

Authors:  Remedios Castello-Cros; Diana Whitaker-Menezes; Alex Molchansky; George Purkins; Louis J Soslowsky; David P Beason; Federica Sotgia; Renato V Iozzo; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

7.  Aging differentially modulates the expression of collagen and collagenase in dermal fibroblasts.

Authors:  M R Khorramizadeh; E E Tredget; C Telasky; Q Shen; A Ghahary
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

Review 8.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

9.  Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.

Authors:  R Stratton; X Shiwen; G Martini; A Holmes; A Leask; T Haberberger; G R Martin; C M Black; D Abraham
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 10.  Mitochondrial Sirtuins in Skin and Skin Cancers.

Authors:  Shengqin Su; Mary Ndiaye; Chandra K Singh; Nihal Ahmad
Journal:  Photochem Photobiol       Date:  2020-04-28       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.